Am J Gastroenterol

1. SHROFF H, Fix OK
   Practical Applications of Artificial Intelligence to Improve Efficiency and Reduce Burnout in Gastroenterology and Hepatology Practices.
   Am J Gastroenterol. 2025 Dec 16. doi: 10.14309/ajg.0000000000003887.
   

   >> Share

   
   
2. CHOI J, Nguyen VH, Przybyszewski E, Song J, et al
   Association of SGLT2 Inhibitors with Reduced Hepatocellular Carcinoma Risk in Patients with Type 2 Diabetes.
   Am J Gastroenterol. 2025 Dec 16. doi: 10.14309/ajg.0000000000003889.
   

   >> Share

   
   

   
   Biochem Biophys Res Commun

3. RASINENI K, Rajamanickam R, Perumal SK, Osna NA, et al
   Betaine supplementation prevents ethanol-induced disruption of intestinal tight junction integrity and liver inflammation in rats.
   Biochem Biophys Res Commun. 2026;794:152997.
   

   >> Share

   
   
4. ZHU Y, Hu M, Xu R, Zhai J, et al
   TARDBP upregulates GJB2 to promote tumor progression in hepatocellular carcinoma.
   Biochem Biophys Res Commun. 2025;796:153123.
   

   >> Share

   
   
5. YANG S, Ko M, Zhang W, Jeong SM, et al
   Splicing factor SF3B4 promotes mitochondrial glutamine metabolism in hepatocellular carcinoma by regulating GLS1 isoform switching.
   Biochem Biophys Res Commun. 2025;796:153134.
   

   >> Share

   
   

   
   BMC Cancer

6. WANG Z, Zhu J, Zhang W, Yang Z, et al
   Association of the YTHDF2 rs3738067 A>G variant with hepatoblastoma risk: a multicenter case-control study in Chinese children.
   BMC Cancer. 2025 Dec 17. doi: 10.1186/s12885-025-15478.
   

   >> Share

   
   

   
   BMC Gastroenterol

7. LONGSOMBOON R, Kachornvitaya P, Prasoppokakorn T, Treeprasertsuk S, et al
   Impact of metabolic and bariatric surgery on MASLD: histological resolution and metabolic outcomes in a retrospective cohort.
   BMC Gastroenterol. 2025;25:864.
   

   >> Share

   
   
8. YI Y, Chen Y, Luo Y
   Aspirin reduces short-term mortality risk in critically ill patients with liver cirrhosis: a propensity-score matched retrospective analysis using the MIMIC-IV database.
   BMC Gastroenterol. 2025 Dec 18. doi: 10.1186/s12876-025-04499.
   

   >> Share

   
   
9. ZHANG S, Akahoshi T, Yoshizumi T, Eto M, et al
   "Noninvasive predictive marker for esophageal variceal bleeding".
   BMC Gastroenterol. 2025 Dec 18. doi: 10.1186/s12876-025-04567.
   

   >> Share

   
   
10. HIOKI T, Imoto K, Goya T, Azuma Y, et al
    Clinicopathological features of steroid-refractory immune-mediated hepatotoxicity induced by immune checkpoint inhibitors.
    BMC Gastroenterol. 2025 Dec 17. doi: 10.1186/s12876-025-04561.
    

    >> Share

    
    
11. HALIMI H, Hesami Z, Asri N, Khorsand B, et al
    Exploring the biliary microbiome in hepatopancreatobiliary disorders: a comprehensive systematic review of microbial signatures and diagnostic potential.
    BMC Gastroenterol. 2025 Dec 17. doi: 10.1186/s12876-025-04551.
    

    >> Share

    
    
12. LI J, Yangjin B, Zhu C, Xu W, et al
    Development of a nomogram for predicting the long-term risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.
    BMC Gastroenterol. 2025;25:860.
    

    >> Share

    
    

    
    Dig Dis Sci

13. DODGE JL, Kim B
    Branched-Chain Amino Acid Supplementation in Patients with Cirrhosis: Boon, Bust, or Bull?
    Dig Dis Sci. 2025 Dec 16. doi: 10.1007/s10620-025-09614.
    

    >> Share

    
    

    
    Endoscopy

14. SHI T, Huang J, Cheng G, Hu D, et al
    A case of cirrhosis with gastric varices and hypersplenism treated by endoscopic ultrasound-guided devascularization and partial splenic embolization (with video).
    Endoscopy. 2025;57.
    

    >> Share

    
    
15. TORRES JJ, Hijioka S, Nagashio Y, Harai S, et al
    Endoscopic recanalization of a complete choledochojejunal anastomotic stricture using the "piercing technique" via an endoscopic ultrasound-guided hepaticogastrostomy approach.
    Endoscopy. 2025;57.
    

    >> Share

    
    

    
    Eur J Pediatr

16. NAJIMI Z, ElSaboni L, Mtegha M, Jayaprakash K, et al
    Analysis of tissue copper levels as a reliable diagnostic tool in paediatric liver disease.
    Eur J Pediatr. 2025;185:23.
    

    >> Share

    
    

    
    Eur Radiol

17. HEO S, Kim HY, Kim S, Choi S, et al
    Performance of simulated abbreviated liver MRI combined with CT for liver metastasis screening in rectal cancer staging.
    Eur Radiol. 2026;36:666-675.
    

    >> Share

    
    
18. SUTTER O, de Senneville BD, Lafitte L, Voyer D, et al
    Toward perioperative, numerically assisted irreversible electroporation for hepatocellular carcinoma: clinical outcomes informed by numerical simulations.
    Eur Radiol. 2025 Dec 19. doi: 10.1007/s00330-025-12223.
    

    >> Share

    
    

    
    Gastrointest Endosc

19. MAGAHIS PT, Hissong E, Hanscom M, Carr-Locke DL, et al
    Outcomes of Endoscopic ultrasound-guided liver biopsy using 22-gauge versus 19-gauge needles with a novel hydrostatic sampling technique.
    Gastrointest Endosc. 2026;103:98-108.
    

    >> Share

    
    

    
    Hepatology

20. RUAN Q, Chen T, Kim M, Yang H, et al
    An alpha-specific PI3K inhibitor improves chemotherapy efficacy by inhibiting hepatic stellate cell activation in liver cancer.
    Hepatology. 2025 Dec 8. doi: 10.1097/HEP.0000000000001639.
    

    >> Share

    
    
21. FORTUNY M, De Rosa A, Roca I, Ouchi D, et al
    Hepatocellular carcinoma with macrovascular invasion: Review and survival meta-analysis of initial local therapy using minimal prognostic criteria.
    Hepatology. 2025 Dec 15. doi: 10.1097/HEP.0000000000001630.
    

    >> Share

    
    
22. LI L, Fang Y, Zhang J, Song M, et al
    Myeloid CD36 deficiency alleviates hepatic fibrosis by promoting adaptive immunity of macrophage.
    Hepatology. 2025 Dec 16. doi: 10.1097/HEP.0000000000001646.
    

    >> Share

    
    
23. KHAN S
    PSC and HCC: Age and cirrhosis draw the line on risk.
    Hepatology. 2026;83:1.
    

    >> Share

    
    
24. WILECHANSKY RM
    Breaching the blood-brain barrier: Functional MRI changes in covert hepatic encephalopathy.
    Hepatology. 2026;83:4-5.
    

    >> Share

    
    
25. PREMKUMAR M, Kajal K
    Reply to 'Nuances in POCUS-guided hemodynamic assessment in cirrhosis'.
    Hepatology. 2025 Dec 17. doi: 10.1097/HEP.0000000000001653.
    

    >> Share

    
    
26. KORATALA A, Argaiz ER
    Nuances in POCUS-guided hemodynamic assessment in cirrhosis.
    Hepatology. 2025 Dec 17. doi: 10.1097/HEP.0000000000001648.
    

    >> Share

    
    
27. HARRISON SA, Dubourg J, Knott M, Colca J, et al
    Hyperinsulinemia, an overlooked clue and potential way forward in metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2026;83:169-177.
    

    >> Share

    
    
28. CARLINI LE, Fernandez AC, Mellinger JL
    Sex and gender in alcohol use disorder and alcohol-associated liver disease in the United States: A narrative review.
    Hepatology. 2026;83:178-194.
    

    >> Share

    
    
29. KOH B, Xiao J, Ng CH, Law M, et al
    Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis.
    Hepatology. 2026;83:117-126.
    

    >> Share

    
    
30. PANAGIOTOPOULOS N, Wolfson T, Harris DT, Batakis D, et al
    Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2026;83:127-141.
    

    >> Share

    
    
31. HAZARI Y, Habbouche L, Garcia Lopez VA, Urra H, et al
    Targeting the ER stress sensor IRE1 protects the liver from fibrosis through the downregulation of the proteostasis factor P4HB/PDIA1.
    Hepatology. 2026;83:75-93.
    

    >> Share

    
    

    
    J Clin Oncol

32. KAWAGUCHI Y, Kashiwabara K, Matsuyama Y, Kokudo N, et al
    Reply to: "Revisiting Methodologic Paradigms in Local Therapies for Hepatocellular Carcinoma: Insights From the SURF Study" and "Methodologic and Reporting Gaps in the SURF Trial".
    J Clin Oncol. 2025 Dec 19:JCO2502390. doi: 10.1200/JCO-25-02390.
    

    >> Share

    
    
33. VITALE A, Mansournia MA, Ponziani FR, Rovetta A, et al
    Revisiting Methodologic Paradigms in Local Therapies for Hepatocellular Carcinoma: Insights From the SURF Study.
    J Clin Oncol. 2025 Dec 19:JCO2501536. doi: 10.1200/JCO-25-01536.
    

    >> Share

    
    

    
    J Hepatol

34. LEVY C, Abouda GF, Bilir BM, Bonder A, et al
    Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial.
    J Hepatol. 2025 May 8:S0168-8278(25)00252-1. doi: 10.1016/j.jhep.2025.
    

    >> Share

    
    
35. ARINO S, Ferrer-Lorente R, Serrano G, Zanatto L, et al
    Patient-derived liver organoids recapitulate liver epithelial heterogeneity and enable precision modeling of alcohol-related liver disease.
    J Hepatol. 2026;84:135-149.
    

    >> Share

    
    
36. XU D, Zhang Z, Zhu Z, Wei W, et al
    Decreased LONP1 expression exacerbates MASH-induced liver fibrosis via elevated orotic acid levels.
    J Hepatol. 2026;84:165-180.
    

    >> Share

    
    
37. MATZ-SOJA M, Berg T, Kietzmann T
    Sex-related variations in liver homeostasis and disease: From zonation dynamics to clinical implications.
    J Hepatol. 2026;84:181-193.
    

    >> Share

    
    
38. VILAR-GOMEZ E, Nephew L, Gawrieh S, Vuppalanchi R, et al
    Healthy eating and physical activity significantly lower sex-specific alcohol-attributable liver mortality in the United States.
    J Hepatol. 2026;84:18-34.
    

    >> Share

    
    
39. DU K, Umbaugh DS, Ren N, Diehl AM, et al
    Cellular senescence in liver diseases: From molecular drivers to therapeutic targeting.
    J Hepatol. 2026;84:194-212.
    

    >> Share

    
    
40. HIRSCHFIELD GM, Kowdley KV, Trivedi PJ, Eksteen B, et al
    Phase II INTEGRIS-PSC trial of bexotegrast, an alphavbeta6/alphavbeta1 integrin inhibitor, in primary sclerosing cholangitis.
    J Hepatol. 2025 Sep 26:S0168-8278(25)02498-5. doi: 10.1016/j.jhep.2025.
    

    >> Share

    
    

    
    N Engl J Med

41. MEYA DB, Cresswell FV, Dai B, Engen N, et al
    Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis.
    N Engl J Med. 2025;393:2434-2446.
    

    >> Share

    
    

    
    PLoS One

42. AYATI FIROOZABADI A, Elahi Vahed I, Lotfi P, Geshani A, et al
    The reciprocal relationship between non-alcoholic fatty liver disease and hypothyroidism: A systematic review and meta-analysis of about 39 million individuals.
    PLoS One. 2025;20:e0338413.
    

    >> Share

    
    
43. BOONKAYA S, Pattarawongpaiboon C, Thaimai P, Ananchuensook P, et al
    Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study.
    PLoS One. 2025;20:e0337351.
    

    >> Share

    
    

    
    Radiology

44. ZHU L, Jiang B, Fei X, Xu Y, et al
    Contrast-enhanced US Evaluation of Residual Hepatocellular Carcinoma Following Lenvatinib Combined with Anti-PD-1 Antibody Downstaging Therapy.
    Radiology. 2025;317:e251698.
    

    >> Share

    
    
45. XIAO Z, Liu X
    Hepatocellular Carcinoma Presenting as Bile Duct Tumor Thrombus without Obvious Intrahepatic Mass.
    Radiology. 2025;317:e251418.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share